Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IPA logo IPA
Upturn stock ratingUpturn stock rating
IPA logo

Immunoprecise Antibodies Ltd (IPA)

Upturn stock ratingUpturn stock rating
$0.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: IPA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4Target price
Low$0.27
Current$0.44
high$1.16

Analysis of Past Performance

Type Stock
Historic Profit -48.53%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 50.80M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 2
Beta 0.22
52 Weeks Range 0.27 - 1.16
Updated Date 06/30/2025
52 Weeks Range 0.27 - 1.16
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.23

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -194.79%
Operating Margin (TTM) -53.47%

Management Effectiveness

Return on Assets (TTM) -14.88%
Return on Equity (TTM) -124.75%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 50579982
Price to Sales(TTM) 2.12
Enterprise Value 50579982
Price to Sales(TTM) 2.12
Enterprise Value to Revenue 2.88
Enterprise Value to EBITDA -4.68
Shares Outstanding 45765100
Shares Floating 41560677
Shares Outstanding 45765100
Shares Floating 41560677
Percent Insiders 5.21
Percent Institutions 8.59

Analyst Ratings

Rating 2
Target Price 4
Buy 2
Strong Buy -
Buy 2
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Immunoprecise Antibodies Ltd

stock logo

Company Overview

overview logo History and Background

Immunoprecise Antibodies Ltd. (IPA) was founded in 1989. It has evolved from a contract research organization to a biotherapeutics discovery company specializing in antibody discovery and development. Over time, it has expanded its technology platforms and service offerings.

business area logo Core Business Areas

  • Antibody Discovery: Provides custom antibody discovery services, including hybridoma technology, B cell cloning, and phage display.
  • Antibody Engineering: Offers antibody optimization, humanization, and antibody engineering services to improve antibody properties.
  • In Vitro and In Vivo Services: Conducts in vitro and in vivo studies to evaluate antibody efficacy and safety.
  • Biomanufacturing: Offers small-scale biomanufacturing services for antibody production.

leadership logo Leadership and Structure

The leadership team includes Jennifer Bath (President & CEO). The company has a board of directors overseeing its operations and strategic direction. It operates with a functional structure, with departments focused on antibody discovery, engineering, and related services.

Top Products and Market Share

overview logo Key Offerings

  • Custom Antibody Discovery: Custom antibody discovery services utilizing various platforms. Competitors include AbCellera, Twist Bioscience, and Ligand Pharmaceuticals. Market share data is not readily available.
  • Phage Display Antibody Libraries: High-diversity phage display antibody libraries. Competitors include Creative Biolabs. Market share data is not readily available.
  • Hybridoma Antibody Production: Traditional hybridoma technology for antibody generation. Competitors include Thermo Fisher Scientific and GenScript. Market share data is not readily available.
  • In Vivo Services: Provides in vivo antibody efficacy and safety testing in animal models. Competitors include Charles River Laboratories. Market share data is not readily available.

Market Dynamics

industry overview logo Industry Overview

The antibody discovery and development market is growing due to increased demand for novel biotherapeutics. Key drivers include advancements in technology, rising prevalence of chronic diseases, and growing investment in R&D.

Positioning

Immunoprecise is positioned as a provider of comprehensive antibody discovery and development services, leveraging multiple technology platforms. It aims to offer a one-stop solution for antibody development.

Total Addressable Market (TAM)

The global antibody market is projected to reach hundreds of billions USD in the next decade. IPA is positioned to capture a portion of this market through its comprehensive service offerings.

Upturn SWOT Analysis

Strengths

  • Diverse technology platforms
  • Comprehensive service offerings
  • Experienced scientific team
  • Strong focus on innovation

Weaknesses

  • Limited brand recognition
  • Smaller scale compared to larger competitors
  • Reliance on service contracts
  • History of losses

Opportunities

  • Expanding into new therapeutic areas
  • Forming strategic partnerships
  • Acquiring complementary technologies
  • Increasing demand for antibody therapeutics

Threats

  • Competition from larger CROs
  • Technological disruptions
  • Economic downturns
  • Regulatory changes

Competitors and Market Share

competitor logo Key Competitors

  • ABCL
  • TWST
  • LIGD

Competitive Landscape

Immunoprecise faces competition from larger and more established CROs and biopharmaceutical companies. It differentiates itself through its diverse technology platforms and comprehensive service offerings.

Major Acquisitions

BioStrand

  • Year: 2022
  • Acquisition Price (USD millions): 14.5
  • Strategic Rationale: Expanded IPAs AI capabilities through BioStrands AI based solutions.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been uneven, with periods of rapid expansion and periods of slower growth or losses.

Future Projections: Future growth is dependent on the company's ability to secure new contracts, develop new technologies, and expand its market presence. Analyst projections are variable and should be assessed by reviewing their analysis.

Recent Initiatives: Recent initiatives include expanding its antibody discovery platforms, forming strategic partnerships, and focusing on high-growth therapeutic areas.

Summary

Immunoprecise Antibodies is a smaller player in a competitive market with diverse technology. Its growth depends on securing contracts, developing new tech, and expanding its market presence. IPA struggles with profitability and limited brand awareness. It faces threats from larger competitors and technological disruptions, and recent acquistions have been made to help growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Third-party Market Research Reports
  • Financial News Outlets

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Immunoprecise Antibodies Ltd

Exchange NASDAQ
Headquaters Austin, TX, United States
IPO Launch date 2017-01-03
CEO, President & Non-Independent Director Dr. Jennifer Lynne Bath Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 72
Full time employees 72

ImmunoPrecise Antibodies Ltd. operates as a techbio company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company's contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies. It is also involved in the development and licensing of antibody discovery platforms and related IP assets. The company was founded in 1983 and is headquartered in Austin, Texas.